Publications by authors named "N V McPhail"
Aims: Androgen deprivation therapy (ADT), usually achieved with luteinising hormone releasing hormone analogues (LHRHa), is central to prostate cancer management. LHRHa reduce both testosterone and oestrogen and are associated with significant long-term toxicity. Previous use of oral oestrogens as ADT was curtailed because of cardiovascular toxicity.
View Article and Find Full Text PDFAbiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 years after the first results. Standard-of-care (SOC) was androgen deprivation therapy.
View Article and Find Full Text PDFPurpose: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data may guide treatment choices.
Methods: A group of patients within the STAMPEDE trial were contemporaneously enrolled with the possibility of being randomly allocated to receive either docetaxel + SOC or AAP + SOC.
Article Synopsis
- The study investigates the presence and impact of structural variations (SVs) at the BRCA1/2 genes in high-grade serous ovarian carcinoma, emphasizing their contribution to homologous recombination repair deficiency (HRD).
- Using whole-genome and RNA sequencing data from 205 tumors, researchers identified significant occurrences of large deletions in addition to known short somatic mutations (SSMs).
- The findings reveal that SVs, often overlooked, significantly affect patient outcomes and suggest that recognizing these variations can enhance patient selection for HRD-targeted therapies.
Background: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design.
Methods: We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy).